0
0
Home > Pharmaceuticals >  Oncology >  Neuroendocrine Tumors (NETs) – Global Drug Forecast and Market Analysis to 2030

Neuroendocrine Tumors (NETs) – Global Drug Forecast and Market Analysis to 2030

The market for neuroendocrine tumors (NETs) – a rare type of tumor where cancerous growth can begin in any cell within the hormone or nervous system – is expected to see a very slow 0.9% compound annual growth rate (CAGR) over the next decade in the world’s eight major markets (8MM*) due to substantial generic erosion and low levels of innovation. This report notes that this may turn around after 2030 with the development of molecules currently in the early-stage pipeline. The NET market will grow from $3.11bn in 2020 to $3.41bn in 2030 across the 8MM.

Sakis Paliouras, PhD, Senior Oncology Analyst at GlobalData, comments: “The most ground-breaking development in the treatment of patients with NETs has been the emergence of peptide receptor radionuclide therapy (PRRT), with the FDA’s approval of Novartis’ Lutathera in 2018. Lutathera has tackled a distinct unmet need for patients progressing on somatostatin analogs and has been very commercially successful so far. GlobalData forecasts the drug to grow further, reaching $699m in peak sales.”

GlobalData expects five pipeline agents to receive marketing authorization in the next decade. Of these, Isotopen Technologien Munchen’s (ITM) PRRT molecule Solucin and Junshi Bio’s immune checkpoint inhibitor Tuoyi are forecast to see the highest clinical use. Furthermore, the newly approved kinase inhibitor Hutchmed’s Sulanda is expected to achieve significant commercial success, with $231m in peak sales.

Paliouras continues: “Four currently marketed agents, Novartis’ Sandostatin LAR and Afinitor, Ipsen’s Somatuline Depot, and Pfizer’s Sutent, are responsible for over 80% of this market’s value. All these agents will go off-patent during the forecast period and experience substantial generic erosion, especially easy-to-manufacture compounds Afinitor and Sutent. This is expected to lead to a great decline in market growth that will only be modestly counterbalanced by approvals of pipeline agents and expansions in new markets.”

“Key opinion leaders (KOLs) interviewed by GlobalData believe that among the most important unmet needs are new predictive biomarkers that can match a patient to the most appropriate therapy, as well as the need for additional insight into when it is feasible to stop treatment or re-treat patients with PRRT. The lack of innovation by current late-stage pipeline agents raises the possibility of a true paradigm shift happening after 2030, coming about by molecules that are now in the early-stage pipeline such as alpha-emitting PRRT drugs and antibody-drug conjugates.”

*8MM = The US, France, Germany, Italy, Spain, the UK, Japan and China

Scope

  • Overview of Neuroendocrine Tumors including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline Neuroendocrine Tumors market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Neuroendocrine Tumor therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II – III).
  • Analysis of the current and future market competition in the global Neuroendocrine Tumor therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

KEY QUESTIONS ANSWERED

  • Five late-stage pipeline agents are expected to enter the Neuroendocrine Tumor market from 2021 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in Neuroendocrine Tumors, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • How has the introduction of Lutathera shaped the 2nd and 3rd lines of therapy? How will the competition fare?
  • What is the expected future uptake of immune checkpoint inhibitors across the 8MM?

Key Highlights

The main drivers of growth include the anticipated approval and launch of five pipeline therapies, in addition to expansions of currently marketed therapies in new markets during the forecast period.

The main barriers to growth in the 8MM are patent expiries and subsequent genericization of the most lucrative agents that are part of the standard of care.

Among the late-stage pipeline products and marketed agents, there is tempered key opinion leader (KOL) excitement as a fundamental change in the field is not expected until the end of the forecast period.

The most important unmet needs in the Neuroendocrine Tumor market include: Predictive biomarkers to guide personalized therapy, safer targeted therapies for patients with low-grade tumors, and more efficacious therapies for high-grade tumors.

Reasons to buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global Neuroendocrine Tumor therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Neuroendocrine Tumor market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global Neuroendocrine Tumor therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

Blueprint Medicines

Bristol Myers Squibb

Camurus AB

Exelixis Inc

Hutchmed

Ipsen Pharma

ITM Isotopen Technologien Munchen

Merck & Co

Novartis

Pfizer

Progenics Pharmaceuticals

Roche

Shanghai Junshi Bioscience

Table of Contents

Table of Contents

| About GlobalData

1 Neuroendocrine Tumors: Executive Summary

1.1 The Neuroendocrine Tumor Market Will Grow at a

0.9% CAGR During 2020-2030

1.2 Key Improvements in Existing Mechanisms of Action Form the Dominant Corporate and R&D Strategy in Neuroendocrine Tumors

1.3 Matching a Patient with the Most Appropriate Therapy Remains the Most Important Unmet Need in Neuroendocrine Tumors

1.4 Low Level of Innovation Across the Late-Stage Pipeline to Introduce Minimal Disruption in the Treatment Landscape

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 8MM Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods: Population – 8MM

4.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs – 8MM

4.4.4 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Type

4.4.5 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Stage and Type

4.4.6 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Grade and Differentiation

4.4.7 Forecast Assumptions and Methods: Five-Year Diagnosed Prevalent Cases of NETs

4.5 Epidemiological Forecast for NETs, 2020-2030

4.5.1 Diagnosed Incident Cases of NETs

4.5.2 Age-Specific Diagnosed Incident Cases of NETs

4.5.3 Sex-Specific Diagnosed Incident Cases of NETs

4.5.4 Diagnosed Incident Cases of NETs by Type

4.5.5 Diagnosed Incident Cases of NETs by Type and Stage at Diagnosis

4.5.6 Diagnosed Incident Cases of NETs by Grade and Differentiation

4.5.7 Five-Year Diagnosed Prevalent Cases of NETs

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of the Analysis

4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL Insights on Disease Management

5.2.1 Diagnosis

5.2.2 Surgical management

5.2.3 Systemic therapy

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Predictive Biomarkers to Match a Patient with the Most Appropriate Therapy

7.3 Safer Targeted Therapies for Low-Grade Tumors and More Efficacious Therapies for High-Grade Tumors

7.4 More Informed Use of Currently Available Drugs

7.5 Well-Tolerated Agents for SSTR Negative Tumors

8 R&D Strategies

8.1 Overview

8.1.1 Enhancing the Validated Strategy of PRRT

8.1.2 Novel Ways to Target SSTRs

8.1.3 Replacing Older Targeted Therapies with Next Generation Kinase Inhibitors and Immune Checkpoint Inhibitors

8.2 Clinical Trials Design

8.2.1 Endpoints More Suitable to NETs

8.2.2 Academically Sponsored and Collaborative Trials

8.2.3 Clinical Trial Challenges

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

12.5 China

12.5.1 Forecast

12.5.2 Key Events

12.5.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.3.2 Diagnosed Patients

13.3.3 Percent Drug-Treated Patients

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologist

13.6.5 Global Director of Therapy Analysis and Epidemiology

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

13.7 Contact Us

List of Tables

Table 1: Neuroendocrine tumors: Key Metrics in the 8MM

Table 2: Grade and Proliferation Segmentation in Neuroendocrine Tumors

Table 3: Risk Factors and Comorbidities for NETs

Table 4: Treatment Guidelines for NETs

Table 5: Top 10 Deals by Value, 2011-2020

Table 6: NET Market – Global Drivers and Barriers, 2020-2030

Table 7: Key Events Impacting Sales for NETs in the US, 2020-2030

Table 8: NET Market – Drivers and Barriers in the US, 2020-2030

Table 9: Key Events Impacting Sales for NETs in the 5EU, 2020-2030

Table 10: NET Market – Drivers and Barriers in the 5EU, 2020-2030

Table 11: Key Events Impacting Sales for NETs in Japan, 2020-2030

Table 12: NET Market – Drivers and Barriers in Japan, 2020-2030

Table 13: Key Events Impacting Sales for NETs in China, 2020-2030

Table 14: NET Market – Drivers and Barriers in China, 2020-2030

Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for NETs in 2020 and 2030

Figure 2: Analysis of the Company Portfolio Gap in NETs During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of NETs During the Forecast Period

Figure 4: Key Therapeutic Targets in Neuroendocrine Tumors

Figure 5: 8MM, Diagnosed Incidence of NETs, Men, Cases per 100,000 Population, All Ages, 2010 and 2020

Figure 6: 8MM, Diagnosed Incidence of NETs, Women, Cases per 100,000 Population, All Ages, 2010 and 2020

Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of NETs

Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Type

Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Stage at Diagnosis, by Type

Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Grade and Differentiation, by Type

Figure 11: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of NETs

Figure 12: 8MM, Diagnosed Incident Cases of NETs, N, Both Sexes, All Ages, 2020

Figure 13: 8MM, Diagnosed Incident Cases of NETs by Age, N, Both Sexes, 2020

Figure 14: 8MM, Diagnosed Incident Cases of NETs by Sex, N, All Ages, 2020

Figure 15: 8MM, Diagnosed Incident Cases of NETs by Type, N, Both Sexes, 2020

Figure 16: 8MM, Diagnosed Incident Cases of NETs by Type and Stage at Diagnosis, N, Both Sexes, All Ages, 2020

Figure 17: 8MM, Diagnosed Incident Cases of NETs by Grade and Differentiation, N, Both Sexes, All Ages, 2020

Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of NETs, N, Both Sexes, All Ages, 2020

Figure 19: Treatment Algorithm for NETs

Figure 20: Unmet Needs and Opportunities in Neuroendocrine Tumors

Figure 21: Overview of the Development Pipeline in NETs

Figure 22: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for NETs in the 8MM During the Forecast Period

Figure 23: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against Afinitor and Lutathera

Figure 24: Analysis of the Company Portfolio Gap in NETs During the Forecast Period

Figure 25: Global (8MM) Sales Forecast by Country for NETs in 2020 and 2030

Figure 26: Sales Forecast by Class for NETs in the US in 2020 and 2030

Figure 27: Sales Forecast by Class for NETs in the 5EU in 2020 and 2030

Figure 28: Sales Forecast by Class for NETs in Japan in 2020 and 2030

Figure 29: Sales Forecast by Class for Neuroendocrine tumors in China in 2020 and 2030

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports